# US 10,500,308 B2 · Decellularized adipose tissue > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,500,308 B2 - Document ID: US10500308B2 - Status: Granted - Kind: B2 - Application number: 14/710,964 - Filed: 2015-05-13 - Published: 2016-02-25 - Granted: 2019-12-10 - Earliest claimed: 2009-12-17 - Assignees: Queen's University at Kingston - Applicants: Queen's University at Kingston - Inventors: Lauren E. Flynn - Web page: https://patentgrep.com/patent/US10500308B2 ## CPC - A61L 27/3604: {characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel} - A61L 27/3683: {subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment} - A61L 27/3834: {Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells} - A61L 27/50: Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials} - A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents - A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like - A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution - C12N 5/0653: {Adipocytes; Adipose tissue} - C12N 11/02: Enzymes or microbial cells immobilised on or in an organic carrier - A61L 2300/64: Animal cells - A61L 2400/04: Materials for stopping bleeding - A61L 2400/06: Flowable or injectable implant compositions - A61L 2430/40: Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking - C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue - A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract This invention provides a method for decellularizing adipose tissue, comprising subjecting the adipose tissue to one or more incubations in an enzymatic digestion solution containing one or more enzymes, and one or more solvent extractions, wherein decellularized adipose tissue comprising an extracellular matrix with well-preserved three-dimensional structure is obtained. The invention also provides a decellularized adipose tissue comprising an extracellular matrix with well-preserved three-dimensional architecture, and bioscaffolds, microcarrier beads, and coatings comprising the decellularized adipose tissue. ## Claims ### Claim 1 A decellularized adipose tissue comprising an extracellular matrix including fibrous collagen and network-type collagen including collagen type IV with basement membrane organization, with well-preserved three-dimensional architecture. ### Claim 2 (depends on 1) The decellularized adipose tissue of claim 1, wherein the decellularized adipose tissue is substantially devoid of intact adipose cells. ### Claim 3 (depends on 1) The decellularized adipose tissue of claim 1, wherein the decellularized adipose tissue is substantially free of immunogenic components. ### Claim 4 (depends on 1) The decellularized adipose tissue of claim 1, including one or more of proteoglycan, glycoprotein, glycosaminoglycan, laminin, or fibronectin. ### Claim 5 (depends on 1) The decellularized adipose tissue of claim 1, for use as a cell culture substrate. ### Claim 6 (depends on 5) The decellularized adipose tissue of claim 5, wherein the cell culture substrate is for cell expansion and/or cell differentiation and/or for the production of bioproducts comprising tissue and one or more proteins. ### Claim 7 (depends on 1) The decellularized adipose tissue of claim 1, comprising at least one additive selected from seeded cells, a biomaterial, a pharmaceutical agent, a hormone, and a growth factor. ### Claim 8 (depends on 1) The decellularized adipose tissue of claim 1, comprising at least one additive selected from a hydrogel and a derivative of one or more of collagen, gelatin, hyaluronan, chondroitin sulphate, chitosan, alginate, silk, fibrin, protein, proteoglycan, glycosaminoglycan, and polysaccharide. ### Claim 9 (depends on 1) The decellularized adipose tissue of claim 1, comprising a hydrogel based on one or more of poly(ethylene glycol) (PEG), polyethylene, polyurethane, polylactic acid (PLA), polyglycolic acid (PGA), and polylactic co-glycolic acid (PLGA. ### Claim 10 (depends on 1) The decellularized adipose tissue of claim 1, wherein the decellularized adipose tissue is digested and solubilized into a liquid. ### Claim 11 (depends on 1) A bioscaffold prepared from the decellularized adipose tissue of claim 1. ### Claim 12 (depends on 11) The bioscaffold of claim 11, for use in a surgical procedure. ### Claim 13 (depends on 12) The bioscaffold of claim 12, wherein the surgical procedure is general surgery, reconstructive surgery, cosmetic surgery, cardiac surgery, orthopaedic surgery, neurosurgery, or urological or gynaecological surgery. ### Claim 14 (depends on 11) The bioscaffold of claim 11, wherein the bioscaffold is used for wound healing applications. ### Claim 15 (depends on 11) The bioscaffold of claim 11, wherein the bioscaffold is used as a hemostatic agent. ### Claim 16 (depends on 11) The bioscaffold of claim 11, comprising one or more materials selected from decellularized extracellular matrix derived from a non-adipose tissue, a synthetic material, a pharmaceutical composition, a hormone, and a growth factor. ### Claim 17 (depends on 11) The bioscaffold of claim 11, wherein the bioscaffold is autologous or allogenic. ### Claim 18 (depends on 11) The bioscaffold of claim 11, wherein the bioscaffold is xenogenic. ### Claim 19 (depends on 10) A scaffold prepared from the decellularized adipose tissue of claim 10. ### Claim 20 (depends on 10) A coating prepared from the decellularized adipose tissue of claim 10. ### Claim 21 (depends on 20) The coating of claim 20, wherein the coating is cross-linked. ### Claim 22 (depends on 10) A microcarrier bead prepared from the decellularized adipose tissue of claim 10. ### Claim 23 (depends on 20) A microcarrier bead including the coating of claim 20. ### Claim 24 (depends on 22) The microcarrier bead of claim 22, for use as a cell and/or drug and/or growth factor delivery vehicle. ### Claim 25 (depends on 22) The microcarrier bead of claim 22, for use as a small volume-bulking agent in cosmetic or reconstructive surgery. ### Claim 26 (depends on 22) The microcarrier bead of claim 22, for use in fabrication of a composite bioscaffold with decellularized adipose tissue. ### Claim 27 (depends on 22) The microcarrier bead of claim 22, wherein the microcarrier bead is cross-linked. ### Claim 28 (depends on 22) The microcarrier bead of claim 22, wherein the microcarrier bead is porous. ### Claim 29 (depends on 1) A particle prepared from the decellularized adipose tissue of claim 1. ### Claim 30 (depends on 20) A particle including the coating of claim 20.